The Long Run with Luke Timmerman Ep178: Peyton Greenside on ML-Guided Biologics Discovery
25 snips
May 13, 2025 Peyton Greenside, co-founder and CEO of BigHat Biosciences, is revolutionizing biologic drug discovery using machine learning. She shares her journey from math enthusiast to CEO, emphasizing the vital role mentorship plays for women in STEM. The discussion dives into how AI and innovative techniques are speeding up antibody design, and the challenges of securing investor confidence in a skeptical industry. With a vision for the future, Greenside reveals how successful early projects can spur rapid advancements in therapeutic development.
AI Snips
Chapters
Transcript
Episode notes
Cell-Free Synthesis Boosts Speed
- Cell-free protein synthesis accelerates antibody production from weeks to days.
- This speed and scale enable testing thousands of antibodies weekly, far beyond cell-based methods.
Unified ML and Synthetic Biology
- Machine learning models predict multiple antibody properties simultaneously from sequence data.
- Combining synthetic biology with AI creates a feedback loop that improves therapeutic design continuously.
Early Cell-Free Antibody Success
- Early proof of concept involved producing 32 antibodies in cell-free systems confirming scalability.
- Initial success showed that making thousands of diverse molecules in cell-free was feasible, a big gamble.